FDA Approves CARBIDOPA, LEVODOPA AND ENTACAPONE — Alembic Pharmaceuticals Inc.

# FDA Approves Generic Carbidopa, Levodopa and Entacapone from Alembic Pharmaceuticals Alembic Pharmaceuticals Inc. received FDA approval for a generic version of carbidopa, levodopa and entacapone on February 5, 2026, expanding treatment options for Parkinson's disease patients and potentially increasing competitive pricing pressure in the neurological therapeutics market. The approval is expected to drive cost savings for patients and payers while strengthening Alembic's position in the growing generic pharmaceutical sector.